173 related articles for article (PubMed ID: 11317201)
1. Is random screening of value in detecting glucocorticoid-remediable aldosteronism within a hypertensive population?
Gates LJ; Benjamin N; Haites NE; MacConnachie AA; McLay JS
J Hum Hypertens; 2001 Mar; 15(3):173-6. PubMed ID: 11317201
[TBL] [Abstract][Full Text] [Related]
2. Genetic screening for glucocorticoid-remediable aldosteronism (GRA): experience of three clinical centres in Poland.
Adler G; Widecka K; Peczkowska M; Dobrucki T; Placha G; Drozd R; Parczewski M; Januszewicz A; Gaciong Z; Ciechanowicz A
J Appl Genet; 2005; 46(3):329-32. PubMed ID: 16110193
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-remediable aldosteronism.
McMahon GT; Dluhy RG
Cardiol Rev; 2004; 12(1):44-8. PubMed ID: 14667264
[TBL] [Abstract][Full Text] [Related]
4. Detecting and treating primary aldosteronism: primary aldosteronism.
Mantero F; Mattarello MJ; Albiger NM
Exp Clin Endocrinol Diabetes; 2007 Mar; 115(3):171-4. PubMed ID: 17427105
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of primary aldosteronism among unselected hypertensive patients: a prospective study based on the use of an aldosterone/renin ratio above 25 as a screening test.
Fogari R; Preti P; Zoppi A; Rinaldi A; Fogari E; Mugellini A
Hypertens Res; 2007 Feb; 30(2):111-7. PubMed ID: 17460380
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting.
Pizzolo F; Trabetti E; Guarini P; Mulatero P; Ciacciarelli A; Blengio GS; Corrocher R; Olivieri O
J Hum Hypertens; 2005 Apr; 19(4):325-7. PubMed ID: 15660117
[No Abstract] [Full Text] [Related]
7. Glucocorticoid-remediable aldosteronism.
Litchfield WR; Dluhy RG; Lifton RP; Rich GM
Compr Ther; 1995 Oct; 21(10):553-8. PubMed ID: 8565422
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid-remediable aldosteronism is associated with severe hypertension in early childhood.
Dluhy RG; Anderson B; Harlin B; Ingelfinger J; Lifton R
J Pediatr; 2001 May; 138(5):715-20. PubMed ID: 11343049
[TBL] [Abstract][Full Text] [Related]
9. [Remediable glucocorticoid hyperaldosteronism: molecular diagnosis].
Lurbe E; Chaves FJ; Torró I; Armengod ME; Alvarez V; Redon J
Med Clin (Barc); 1999 Nov; 113(15):579-82. PubMed ID: 10605685
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid-remediable aldosteronism.
Dluhy RG; Lifton RP
Endocrinol Metab Clin North Am; 1994 Jun; 23(2):285-97. PubMed ID: 8070423
[TBL] [Abstract][Full Text] [Related]
11. Normokalemic hyperaldosteronism in patients with resistant hypertension.
Benchetrit S; Bernheim J; Podjarny E
Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of primary aldosteronism.
Mulatero P; Monticone S; Bertello C; Tizzani D; Iannaccone A; Crudo V; Veglio F
Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):188-93. PubMed ID: 20389241
[TBL] [Abstract][Full Text] [Related]
13. Primary aldosteronism: renaissance of a syndrome.
Young WF
Clin Endocrinol (Oxf); 2007 May; 66(5):607-18. PubMed ID: 17492946
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoid-remediable aldosteronism in a large kindred: clinical spectrum and diagnosis using a characteristic biochemical phenotype.
Rich GM; Ulick S; Cook S; Wang JZ; Lifton RP; Dluhy RG
Ann Intern Med; 1992 May; 116(10):813-20. PubMed ID: 1567095
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism.
Fallo F; Pilon C; Williams TA; Sonino N; Morra Di Cella S; Veglio F; De Iasio R; Montanari P; Mulatero P
J Hum Hypertens; 2004 Jan; 18(1):47-51. PubMed ID: 14688810
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism.
Litchfield WR; New MI; Coolidge C; Lifton RP; Dluhy RG
J Clin Endocrinol Metab; 1997 Nov; 82(11):3570-3. PubMed ID: 9360508
[TBL] [Abstract][Full Text] [Related]
17. Clinical and gene mutation studies on a Chinese pedigree with glucocorticoid-remediable aldosteronism.
Ding W; Liu L; Hu R; Xu M; Chen J
Chin Med J (Engl); 2002 Jul; 115(7):979-82. PubMed ID: 12150724
[TBL] [Abstract][Full Text] [Related]
18. Abolished nocturnal blood pressure fall in a boy with glucocorticoid-remediable aldosteronism.
Seeman T; Widimský J; Hampf M; Bernhardt R
J Hum Hypertens; 1999 Dec; 13(12):823-8. PubMed ID: 10618671
[TBL] [Abstract][Full Text] [Related]
19. Primary aldosteronism: an update on screening, diagnosis and treatment.
Rossi GP; Pessina AC; Heagerty AM
J Hypertens; 2008 Apr; 26(4):613-21. PubMed ID: 18327065
[TBL] [Abstract][Full Text] [Related]
20. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases.
Médeau V; Moreau F; Trinquart L; Clemessy M; Wémeau JL; Vantyghem MC; Plouin PF; Reznik Y
Clin Endocrinol (Oxf); 2008 Jul; 69(1):20-8. PubMed ID: 18284637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
